A5051082265- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Psychosomatic Disorders and Their Treatments
- Ophthalmology and Eye Disorders
- Cardiovascular Syncope and Autonomic Disorders
- COVID-19 diagnosis using AI
- Stock Market Forecasting Methods
- COVID-19 epidemiological studies
- Olfactory and Sensory Function Studies
- Neurological Disorders and Treatments
- Financial Markets and Investment Strategies
- Neuroscience of respiration and sleep
- Anomaly Detection Techniques and Applications
- Nicotinic Acetylcholine Receptors Study
- Advanced Combustion Engine Technologies
- Neuropeptides and Animal Physiology
- Respiratory and Cough-Related Research
- Neurological Complications and Syndromes
- Carcinogens and Genotoxicity Assessment
- Probabilistic and Robust Engineering Design
- Advanced Control Systems Optimization
- Botulinum Toxin and Related Neurological Disorders
- Body Image and Dysmorphia Studies
- X-ray Spectroscopy and Fluorescence Analysis
Charité - Universitätsmedizin Berlin
2016-2025
Universitätsmedizin Greifswald
2021-2025
Humboldt-Universität zu Berlin
2000-2025
Freie Universität Berlin
2021-2025
King's College London
2017-2024
Novartis (India)
2021-2024
Amgen (United States)
2017-2024
West German Heart and Vascular Center Essen
2024
TU Dresden
2009-2023
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2023
We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for prevention of episodic migraine.We randomly assigned patients to receive subcutaneous injection either at dose 70 mg or 140 mg, placebo monthly 6 months. The primary end point was change from baseline months 4 through in mean number migraine days per month. Secondary points were 50% greater reduction month, use acute migraine-specific medication, and scores on...
Several outbreak prediction models for COVID-19 are being used by officials around the world to make informed decisions and enforce relevant control measures. Among standard global pandemic prediction, simple epidemiological statistical have received more attention authorities, these popular in media. Due a high level of uncertainty lack essential data, shown low accuracy long-term prediction. Although literature includes several attempts address this issue, generalization robustness...
Background Chronic cluster headache (CH) is a debilitating disorder for which few well-controlled studies demonstrate effectiveness of available therapies. Non-invasive vagus nerve stimulation (nVNS) was examined as adjunctive prophylactic treatment chronic CH. Methods PREVA prospective, open-label, randomised study that compared nVNS ( n = 48) with standard care (SoC) alone (control 49)). A two-week baseline phase followed by four-week (SoC plus vs control) and extension nVNS). The primary...
Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief acute and preventive treatments. It is aim present document to provide a definition those migraines which are difficult-to-treat, create awareness existence this group patients, help Healthcare Authorities understanding implications, basis develop better pathophysiological support further therapeutic advances.Definitions were established consensus process using Delphi...
To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody, in patients with chronic migraine and medication overuse.In this double-blind, placebo-controlled study, 667 adults were randomized (3:2:2) to placebo or erenumab (70 140 mg), stratified by region overuse status. Data from baseline at used assess changes monthly days, acute migraine-specific treatment proportion achieving ≥50% reduction days.Of randomized, 41% (n = 274) met...
Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life studies lasting 3 to 12 months, little is known about long-term therapy.This study was an open-label, 5-year treatment phase following a 12-week, double-blind, placebo-controlled trial adults with episodic migraine. Patients initially received open-label 70 mg, which increased 140 mg protocol amendment. Efficacy analyses included change from baseline monthly days (MMDs), acute...
Background We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to calcitonin gene-related peptide receptor, topiramate for migraine prophylaxis in adults. Methods HER-MES was 24-week, randomised, double-blind, double-dummy, controlled trial conducted 82 sites Germany. Patients with ≥4 days per month naïve study drugs were randomly assigned (1:1) either subcutaneous erenumab (70 or 140 mg/month) plus placebo (erenumab group) oral at individual dose optimal...
Nitric oxide (NO) has been implicated in migraine pathogenesis based on the delayed development of typical headache 4–6 h after infusing NO donor nitroglycerin [glyceryl trinitrate (GTN)] to migraineurs. Furthermore, inhibiting synthesis by treatment with a synthase (NOS) inhibitor attenuates spontaneous headaches 67% subjects. Because linked inflammation and cytokine expression, we investigated consequences brief GTN infusion (30 min) meningeal rat model using doses relevant human model. We...
Object. The pathogenesis of delayed ischemic neurological deficits after subarachnoid hemorrhage has been related to products hemolysis. Topical brain superfusion artificial cerebrospinal fluid (ACSF) containing the hemolysis K + and hemoglobin (Hb) was previously shown induce ischemia in rats. Superimposed on a slow vasospastic reaction, events represent spreading depolarizations neuronal—glial network that trigger acute vasoconstriction. purpose present study investigate whether such...
Methods: Four hundred and sixty-one adult subjects with migraine were randomised to one of five treatments, the oral antagonist at calcitonin gene-related peptide (CGRP) receptor BI 44370 TA (50 mg, 200 400 mg), active comparator eletriptan 40 mg or placebo. The analysis included 341 who took study medication. Results: primary endpoint, pain-free after two hours, was reached by significantly more in (20/73 = 27.4%) (24/69 34.8%) groups compared placebo (6/70 8.6%, p .0016), but not group...
The aim of this study was to investigate the efficacy riboflavin for prevention migraine. An open label performed in a specialized outpatient clinic. Patients received 400 mg capsules per day. Headache frequency, duration, intensity and use abortive drugs were recorded at baseline 3 6 months after treatment. frequency significantly reduced from 4 days/month 2 ( P < 0.05). decreased 7 units/month 4.5 treatment In contrast, headache hours did not change significantly. We could demonstrate...